IRVINE, Calif., April 25, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against U.S. Concrete, Inc. (“U.S. Concrete” or the “Company”) (Nasdaq:USCR). Investors who purchased or otherwise acquired shares between March 6, 2015 and March 23, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 30, 2017 lead plaintiff motion deadline.
If you purchased U.S. Concrete shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, U.S. Concrete made false and misleading statements and/or failed to disclose that the Company lacked effective internal controls over financial reporting, and thus its public statements were materially false and misleading at all relevant times. On March 24, 2017, U.S. Concrete filed a Current Report on Form 8-K with the Securities & Exchange Commission, announcing the resignation of its CFO Joseph Tusa, and advising investors that the Company replaced its previous auditor, Grant Thornton LLP, with Ernst & Young LLP as its new public accounting firm. When this information was released to the public, shares of the Company dropped in value materially, which caused investors harm.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 



